Reimbursement of Orphan Drugs in Belgium: What (Else) Matters?

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/s13023-014-0139-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Psy147 - Availability and Reimbursement of Orphan Drugs in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the Netherlands

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Chloride, What Else?

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy159 - Comparison of Orphan Drug Prices: Belgium vs Luxembourg

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Yes, Yes, IL-6: What Else?

Journal of Applied Physiology
MedicinePhysiologySports Science
2010English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy